GMGiulia Masuelli

Giulia Masuelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giulia Masuelli has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vaginal delivery in women with HIV in Italy: results of 5 years of implementation of the national SIGO-HIV protocol

    by for SIGO-HIV Study Group, Cecilia Tibaldi, Giulia Masuelli, Matilde Sansone, Beatrice Tassis, Irene Cetin, Laura Franceschetti, Arsenio Spinillo, Giuliana Simonazzi, Antonella Vimercati, et al.

    To evaluate the maternal and neonatal safety of vaginal delivery in women with HIV following the implementation of a national protocol in Italy.


  • Open Access

    Pregnant with HIV before age 25: data from a large national study in Italy, 2001–2016

    by M. Floridia, G. Masuelli, E. Tamburrini, I. Cetin, G. Liuzzi, P. Martinelli, G. Guaraldi, A. Spinillo, A. Vimercati, G. Maso, et al.

    SUMMARY: Young pregnant women with HIV may be at significant risk of unplanned pregnancy, lower treatment coverage, and other adverse pregnancy outcomes. In a large cohort of pregnant women with HIV in Italy, among 2979 pregnancies followed in 2001–2016, 9·0% were in women P< 0·001). Younger women had a lower rate of planned pregnancy (23·2%vs.37·7%, odds ratio (OR) 0·50, 95% confidence interval (CI) 0·36–0·69), were more frequently diagnosed with HIV in pregnancy (46·5%vs.20·9%, OR 3·29, 95% CI 2·54–4·25), and, if already diagnosed with HIV before pregnancy, were less frequently on antiretroviral treatment at conception (vs.99·3%), with no differences in rate of HIV viral suppression at third trimester and adverse pregnancy outcomes. The data show that young women represent a growing proportion of pregnant women with HIV, and are significantly more likely to have unplanned pregnancy, undiagnosed HIV infection, and lower treatment coverage at conception. During pregnancy, antiretroviral treatment, HIV suppression, and pregnancy outcomes are similar compared with older women. Earlier intervention strategies may provide additional benefits in the quality of care for women with HIV.


  • Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV

    by M. Floridia, M.F. Pirillo, A. Molinari, E. Tamburrini, C. Pinnetti, G. Guaraldi, G. Nardini, G. Masuelli, S. Dalzero, I. Cetin, et al.


  • Open Access

    Amniocentesis and chorionic villus sampling in HIV‐infected pregnant women: a multicentre case series

    by M Floridia, G Masuelli, A Meloni, I Cetin, E Tamburrini, Af Cavaliere, S Dalzero, M Sansone, S Alberico, B Guerra, et al.

    Objectives: To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures.Design: Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used.Setting: University and hospital clinics.Population: Pregnant women with HIV.Methods: Temporal trends were analysed by analysis of variance and by the Chi‐square test for trend. Quantitative variables were compared by Student's t‐test and categorical data by the Chi‐square test, with odds ratios and 95% confidence intervals calculated.Main outcome measures: Rate of invasive testing, intrauterine death, HIV transmission.Results: Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005.Conclusions: The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment.Tweetable No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti‐HIV regimens.